Skip Navigation


Rheumatology Advance Access originally published online on September 1, 2004
Rheumatology 2004 43(12):1555-1560; doi:10.1093/rheumatology/keh384
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary data
Right arrow All Versions of this Article:
43/12/1555    most recent
keh384v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mikdashi, J.
Right arrow Articles by Handwerger, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mikdashi, J.
Right arrow Articles by Handwerger, B.
Related Collections
Right arrow Systemic Lupus Erythematosus and Autoimmunity
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology Vol. 43 No. 12 © British Society for Rheumatology 2004; all rights reserved

PAPER

Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort

J. Mikdashi and B. Handwerger

University of Maryland School of Medicine, Baltimore, MD, USA.

Correspondence to: J. Mikdashi, Division of Rheumatology and Clinical Immunology, 10 South Pine Street, Suite 834, Baltimore, MD 21201, USA. E-mail: jmikdash{at}umaryland.edu.

Objective. To identify factors predictive of significant neuropsychiatric (NP) damage in systemic lupus erythematosus (SLE).

Methods. One hundred and thirty patients with SLE were followed at the University of Maryland Lupus Clinic from 1992 until 2003. NP manifestations were defined according to the revised American College of Rheumatology (ACR) nomenclature and case definitions for NP–SLE syndromes. Disease activity was measured using the SLE Disease Activity Index (SLEDAI), organ damage using the Systemic Lupus International Collaborating Clinics Damage Index SLICC/ACR (SDI); NP damage (NPDI) was measured with the corresponding domain of the SDI. At end of study period, 64 patients exhibited no NP damage (NPDI = 0) and 66 patients developed significant NP damage (defined as NPDI ≥1). The baseline features for these two patient groups were compared, and variables found to be significantly different were examined by multivariable analyses to determine their contribution to NP damage.

Results. Significant NP damage is common in SLE; mortality is infrequent and the cause of death is unrelated to NP damage. Independent predictors of significant NP damage were disease activity, Caucasian ethnicity and the presence of antiphospholipid antibodies and anti-Ro/SSA antibody. Certain clinical features at baseline predicted specific NP damage. For example, higher disease activity at baseline was predictive of psychosis and cognitive impairment, anti-dsDNA was predictive of polyneuropathy, and antiphospholipid antibodies were predictive of seizures and cerebrovascular accidents.

Conclusions. In this longitudinal SLE cohort, significant cumulative NP damage occurred. Early aggressive therapy targeted towards NP manifestations may prevent the occurrence of NP damage.

KEY WORDS: Systemic lupus erythematosus, Neuropsychiatric damage, Risk factors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 PsychosomaticsHome page
L. Wittmann, T. Sensky, L. Meder, B. Michel, T. Stoll, and S. Buchi
Suffering and Posttraumatic Growth in Women With Systemic Lupus Erythematosus (SLE): A Qualitative/Quantitative Case Study
Psychosomatics, July 1, 2009; 50(4): 362 - 374.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
J. M. Pego-Reigosa and D. A. Isenberg
Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease
Rheumatology, October 1, 2008; 47(10): 1498 - 1502.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
C. M. Everett, T. D. Graves, S. Lad, H. R. Jager, M. Thom, D. A. Isenberg, and M. G. Hanna
Aggressive CNS lupus vasculitis in the absence of systemic disease activity
Rheumatology, January 1, 2008; 47(1): 107 - 109.
[Full Text] [PDF]

Home page
 LupusHome page
T. Avcin and E. Silverman
Review: Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome
Lupus, August 1, 2007; 16(8): 627 - 633.
[Abstract] [PDF]

Home page
 LupusHome page
A.M. Bertoli, L.M. Vila, M. Apte, B.J. Fessler, H.M. Bastian, J.D. Reveille, and G.S. Alarcon
Systemic lupus erythematosus in a multiethnic US Cohort LUMINA XLVIII: factors predictive of pulmonary damage
Lupus, June 1, 2007; 16(6): 410 - 417.
[Abstract] [PDF]

Home page
 LupusHome page
L M Vila, M J Molina, A M Mayor, R A Peredo, M L Santaella, and S Vila
Clinical and prognostic value of autoantibodies in Puerto Ricans with systemic lupus erythematosus
Lupus, December 1, 2006; 15(12): 892 - 898.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.